Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates

Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates

Matuzumab and nimotuzumab are anti-EGFR monoclonal antibodies that bind to different epitopes of domain III of EGFR. We developed <sup>89</sup>Zr-matuzumab as a PET probe for diagnosis/monitoring of response to treatment of a noncompeting anti-EGFR nimotuzumab antibody drug conjugate (AD...

Full description

Bibliographic Details
Main Authors:	Anjong Florence Tikum, Anand Krishnan Nambisan, Jessica Pougoue Ketchemen, Hanan Babeker, Musharraf N. Khan, Emina E. Torlakovic, Humphrey Fonge
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Series:	Pharmaceutics
Subjects:	<sup>89</sup>Zr-matuzumab epitope-specific immunoconjugates nimotuzumab antibody drug conjugate PET/CT imaging colorectal cancer EGFR
Online Access:	https://www.mdpi.com/1999-4923/14/9/1917

Similar Items

<sup>89</sup>Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo
by: Elahe Alizadeh, et al.
Published: (2021-02-01)

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
by: Puey-Ling Chia, et al.
Published: (2020-10-01)

[<sup>89</sup>Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
by: Adriana V. F. Massicano, et al.
Published: (2023-05-01)

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body <sup>18</sup>F-Fluorodeoxyglucose and <sup>89</sup>Zr-Rituximab PET Scans
by: Bart M. de Vries, et al.
Published: (2022-02-01)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
by: Yanping Huang, et al.
Published: (2023-09-01)

<sup>89</sup>Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs
by: Iris H. C. Miedema, et al.
Published: (2023-11-01)

Preclinical PET and MR Evaluation of <sup>89</sup>Zr- and <sup>68</sup>Ga-Labeled Nanodiamonds in Mice over Different Time Scales
by: Gordon Winter, et al.
Published: (2022-12-01)

Current Perspectives on <sup>89</sup>Zr-PET Imaging
by: Joon-Kee Yoon, et al.
Published: (2020-06-01)

Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review
by: Elizabeth Katherine Anna Triumbari, et al.
Published: (2022-07-01)

Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of <sup>89</sup>Zr Immune-PET Tracers
by: Ryota Imura, et al.
Published: (2021-08-01)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
by: Xiaoting Ma, et al.
Published: (2023-04-01)

Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent
by: Hanan Babeker, et al.
Published: (2022-12-01)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
by: Tania Crombet, et al.
Published: (2011-04-01)

Biodistribution of Mesenchymal Stromal Cells Labeled with [<sup>89</sup>Zr]Zr-Oxine in Local Radiation Injuries in Laboratory Animals
by: Tatiana A. Astrelina, et al.
Published: (2023-10-01)

Image-Based Dosimetry in Dogs and Cross-Reactivity with Human Tissues of IGF2R-Targeting Human Antibody
by: Kevin J. H. Allen, et al.
Published: (2023-07-01)

Evaluation of Chelator-to-Antibody Ratio on Development of <sup>89</sup>Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor
by: Shih-Chuan Tsai, et al.
Published: (2023-12-01)

Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
by: Helen Damerow, et al.
Published: (2022-10-01)

ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer
by: Ziqi Li, et al.
Published: (2023-03-01)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
by: Mika K. Kaneko, et al.
Published: (2018-07-01)

Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma
by: Run-Jie Wang, et al.
Published: (2024-03-01)

An Epitope on EGFR Loading Catastrophic Internalization Serve as a Novel Oncotarget for Hepatocellular Carcinoma Therapy
by: Dianshuai Huang, et al.
Published: (2020-02-01)

Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees
by: Jose Mateus, et al.
Published: (2020-11-01)

Side-by-Side Comparison of Five Chelators for <sup>89</sup>Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability
by: Helen Damerow, et al.
Published: (2021-12-01)

Immuno-PET Imaging of Atherosclerotic Plaques with [<sup>89</sup>Zr]Zr-Anti-CD40 mAb—Proof of Concept
by: Kikkie Poels, et al.
Published: (2022-03-01)

Pyrotinib Targeted EGFR-STAT3/CD24 Loop-Mediated Cell Viability in TSC
by: Xiao Han, et al.
Published: (2022-09-01)

Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model
by: Vincenzo Di Leo, et al.
Published: (2021-04-01)

PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models
by: Tae Sup Lee, et al.
Published: (2018-10-01)

Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11
by: Benedikt Judmann, et al.
Published: (2023-02-01)

Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors
by: Maryam Oroujeni, et al.
Published: (2018-09-01)

Precise Half-Life Values for Two-Neutrino Double-<i>β</i> Decay: 2020 Review
by: Alexander Barabash
Published: (2020-09-01)

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain
by: Reyhaneh Manafi-Farid, et al.
Published: (2020-08-01)

Production and Semi-Automated Processing of <sup>89</sup>Zr Using a Commercially Available TRASIS MiniAiO Module
by: Vijay Gaja, et al.
Published: (2020-06-01)

Enhancing Control of <i>Leishmania infantum</i> Infection: A Multi-Epitope Nanovaccine for Durable T-Cell Immunity
by: Clara Hurtado-Morillas, et al.
Published: (2024-02-01)

Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-<i>b</i>]indol-3-one Derivatives as Potent Inhibitors of EGFR<sup>T790M</sup>/BRAF<sup>V600E</sup> Pathways
by: Lamya H. Al-Wahaibi, et al.
Published: (2023-01-01)

Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging
by: Pamela Leland, et al.
Published: (2023-06-01)

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
by: Mario Occhipinti, et al.
Published: (2021-05-01)

How Can the Introduction of Zr<sup>4+</sup> Ions into TiO<sub>2</sub> Nanomaterial Impact the DSSC Photoconversion Efficiency? A Comprehensive Theoretical and Experimental Consideration
by: Aleksandra Bartkowiak, et al.
Published: (2021-05-01)

EGFR–c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells
by: Sung-Min Kwak, et al.
Published: (2019-08-01)

Identification of Novel Candidate CD8<sup>+</sup> T Cell Epitopes of the SARS-CoV2 with Homology to Other Seasonal Coronaviruses
by: Pradeep Darshana Pushpakumara, et al.
Published: (2021-05-01)

Nimotuzumab y gemcitabina en el tratamiento del cáncer de páncreas y metástasis esplénica
by: Ángel Piriz Momblant, et al.
Published: (2019-07-01)